Natixis Advisors, L.P. Myriad Genetics Inc Transaction History
Natixis Advisors, L.P.
- $46 Billion
- Q2 2024
A detailed history of Natixis Advisors, L.P. transactions in Myriad Genetics Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 275,367 shares of MYGN stock, worth $6.05 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
275,367
Previous 238,365
15.52%
Holding current value
$6.05 Million
Previous $5.08 Million
32.53%
% of portfolio
0.01%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding MYGN
# of Institutions
238Shares Held
92.7MCall Options Held
117KPut Options Held
113K-
Black Rock Inc. New York, NY15.2MShares$333 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$221 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA8.26MShares$181 Million0.04% of portfolio
-
Camber Capital Management LP Boston, MA5.5MShares$121 Million3.72% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.4MShares$96.6 Million0.05% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $1.77B
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...